Results 251 to 260 of about 182,825 (308)

Indications and Efficacy of Progestogen‐Monotherapy as Menopause Hormone Therapy: A Narrative Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT Menopausal hormone therapy (MHT) remains the most effective treatment for vasomotor symptoms (VMS) and other manifestations of menopause; however, its use is limited in women with contraindications to oestrogen. Progestogen monotherapy, though historically underutilized, represents a viable alternative in this population. This narrative review
Chloe Thomas, Olivia Carere, Lauren Clarfield, Michelle Jacobson   +3 more
wiley   +1 more source

CRB2 Facilitates Epithelial Ovarian Cancer Progression by Inducing Polarity Changes via Activation of the Wnt/PCP Signalling Pathway. [PDF]

J Cell Mol Med
Tao C, Li S, Sun D, Zhou J, Chen Y, Zhang R, Ni X.   +6 more
europepmc   +1 more source

BRD9 inhibition as potential treatment option for testicular germ cell tumors

Andrology, EarlyView.
Abstract Background Testicular germ cell tumors (TGCT) are the predominant tumor in younger males. Usually, 5‐year survival rates are quite high, but 15–20% of patients with metastatic non‐seminomas are resistant to standard cisplatin‐based therapy.
Aylin Hansen, Christine Sanders, Florian Fronhoffs, Kai Funke, Glen Kristiansen, Hubert Schorle   +5 more
wiley   +1 more source

Cutibacterium acnes-Derived Extracellular Vesicles Promote Epithelial Ovarian Cancer Progression by Activating the KEAP1-NRF2 Antioxidant Pathway to Suppress Ferroptosis. [PDF]

Microb Biotechnol
Huang Q, Chen Q, Xiong W, Sun Y, Huang Y, Dai A, Chen J, Wu X, Jiang Y, Wei F, Chen Q, Chen T.   +11 more
europepmc   +1 more source

Inhibition of HMGA2 Leads to Reduced Cell Proliferation and Increased Apoptosis in Human Embryonal Carcinoma Cell Lines

Andrology, EarlyView.
ABSTRACT Background The most prevalent solid tumors in young men are testicular germ cell tumors (TGCTs), and embryonal carcinoma is the most common subtype among non‐seminomatous germ cell tumors (NSGCTs). Despite the excellent cure rates of cisplatin‐based chemotherapy, resistance develops in 15%–30% of patients with metastatic cancer, which results ...
Marco De Martino, Matteo Lampitto, Alfredo Fusco, Marco Barchi, Francesco Esposito, Paolo Chieffi   +5 more
wiley   +1 more source

Plasma cell-free DNA 5-hydroxymethylcytosine signatures as predictive biomarkers for platinum resistance and prognosis in epithelial ovarian cancer. [PDF]

J Ovarian Res
Xue Y, Zhang L, Chen X, Yi Z, Huang C, Yu P, Zheng M, Yang Z, Li H, Wang D, Xu S, Guo H, Zhao L, Lin J, Chen L.   +14 more
europepmc   +1 more source

T Cell Microenvironmental Impacts and Therapeutic Opportunities: Application to Human Testicular Germ Cell Tumors

Andrology, EarlyView.
ABSTRACT Testicular germ cell tumors (TGCT) are the leading malignancy in adolescent and young adult males, yet the immunological and cellular mechanisms governing their tumor microenvironment (TME) remain poorly understood. Here, we present a comprehensive review of TGCT pathobiology with a focus on the immune landscape, particularly the role of tumor‐
R Islam, M Figura, J Heyer, S Lieber, M Huber, KL Loveland, HC Schuppe, Daniela Fietz   +7 more
wiley   +1 more source

A decision-support tool for management of advanced epithelial ovarian cancer in a single centre in India (CT PAUSE Nomogram): a prospective Study (2022-2024). [PDF]

Lancet Reg Health Southeast Asia
Jeslin AG, Natarajan S, Hiriyanna S, Ninan R, Cecil GH, Simon B, Eapen A, Thomas V, Thomas A, Varghese KM, Joel A, Singh A, Karuppusami R, Chandramohan A.   +13 more
europepmc   +1 more source

Development and validation of a nomogram for predicting recurrence in epithelial ovarian cancer after primary cytoreductive surgery: A single-center retrospective study. [PDF]

Pak J Med Sci
Zhang W, Shu Y, Wan Z, Yang S.
europepmc   +1 more source

Quality of Life Measurement in PARP Inhibitor Trials of Epithelial Ovarian Cancer - What Do We Know? [PDF]

Cancer Control
Kumari S, Umadevi K, Sundeep D.
europepmc   +1 more source